Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Summary:
Tuberculosis (TB) kills more people than any other pathogen and the only licenced vaccine, BCG, is ineffective in most of the world. There is an urgent need for a better vaccine, but TB vaccine development is scientifically challenging. An update on global progress in TB vaccine R&D, together with an overview of the development of a TB controlled human infection model using BCG will be given.
The development of a vaccine against SARS CoV2 was happily much easier than TB vaccine development. However, a SARS CoV2 controlled human infection model would still have utility in drug and vaccine R&D and an overview of the status of a SARS CoV2 controlled human infection model will also be provided.
Bio
Helen McShane FRCP, PhD, FMedSci is Director, NIHR Oxford Biomedical Research Centre; Professor of Vaccinology, University of Oxford; Deputy Head, Medical Sciences Division and an Honorary Consultant Physician in Infectious Diseases.
Since 2001, Helen has lead the TB vaccine research group at the University of Oxford, and has expertise in vaccine design through to phase IIb efficacy testing. She led the development of the first candidate TB vaccine to enter efficacy testing, and now works on alternate routes of delivery and the development of controlled human infection models for TB and SARS CoV2.
